Skip to content

A study on the efficacy of iTBS treatment for late-life depression with cognitive impairment and its impact on the cognitive control network

A study on the efficacy of iTBS treatment for late-life depression with cognitive impairment and its impact on the cognitive control network

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108312
Enrollment
Unknown
Registered
2025-08-28
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric depression

Interventions

Sponsors

Capital Medical University Affiliated Beijing Anding Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Initial onset age of 60 years or older; 2. Meeting the diagnostic criteria for depressive disorders as outlined in the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5); 3. A total score of 17 or higher on the Hamilton Depression Rating Scale-17 (HAMD-17); 4.Educational attainment of at least primary school level, capable of cooperating to complete assessment examinations; 5.A score of less than 26 on the Montreal Cognitive Assessment (MOCA); 6. Written informed consent obtained from the individual or their family.

Exclusion criteria

Exclusion criteria: 1. A history of previous cranial diseases, brain injuries, epileptic seizures, and other neurological diseases; 2. Having severe or unstable cardiovascular, respiratory, immune, or other systemic diseases; 3. A history of or current diagnosis via DSM-5 of the following mental illnesses: organic mental disorders, Alzheimer's disease, secondary dementia caused by other reasons, schizophrenia, schizoaffective disorder, bipolar affective disorder, delusional disorder, unspecified mental illness, alcohol (or drug) dependence or abuse, and personality disorders; 4. Having contraindications to nuclear magnetic resonance or transcranial magnetic therapy: such as having electronic or metal implants in the body (dentures, arterial clips, pacemakers, or metal fixators, etc.), claustrophobia, etc.; 5. Depressive states caused by other systemic diseases and organic brain lesions; 6. A history of alcohol or morphine drug abuse;

Design outcomes

Primary

MeasureTime frame
Depressive symptom ;

Secondary

MeasureTime frame
cognitive function;

Countries

China

Contacts

Public ContactRen Li

Beijing Anding Hospital, Capital Medical University

18618180828@163.com+86 186 1818 0828

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026